1. Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. (October 2022) Authors: Fontana, E.; Williams, A.; Falchook, G.; Lakhani, N.; Evans, T.R.J.; Gondi, V.; Iwamoto, F.; McKean, M.; Symeonides, S.; Butowski, N.; McLaren, A.; Henry, J.; Buerki, R.; Rotolo, J.; Capiaux, G.; Michel, R.; Kaesshaefer, S.; Wiegert, E.; Bexon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗